Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PACRITINIB for Marrow hyperplasia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 17 adverse event reports in the FDA FAERS database where PACRITINIB was used for Marrow hyperplasia.

Most Reported Side Effects for PACRITINIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 536 20.9% 13 64
Off label use 459 17.9% 33 56
Fatigue 320 12.5% 9 40
Product dose omission issue 279 10.9% 6 60
Death 261 10.2% 260 23
Nausea 246 9.6% 8 36
Platelet count decreased 237 9.3% 4 42
Haemoglobin decreased 171 6.7% 5 43
Asthenia 119 4.6% 5 22
Drug ineffective 98 3.8% 2 9
Dizziness 96 3.8% 4 12
Splenomegaly 84 3.3% 2 11
Transfusion 83 3.2% 1 23
Constipation 75 2.9% 2 9
Dyspnoea 75 2.9% 3 23

Other Indications for PACRITINIB

Myelofibrosis (1,586) Myeloproliferative neoplasm (365) Product used for unknown indication (154) Myelodysplastic syndrome (112) Polycythaemia vera (112) Essential thrombocythaemia (66) Acute myeloid leukaemia (21) Thrombocytopenia (21) Chronic myelomonocytic leukaemia (13) Immune thrombocytopenia (12)

Other Drugs Used for Marrow hyperplasia

RUXOLITINIB (12) THALIDOMIDE (6) CYTARABINE (5) IDARUBICIN (5) LENALIDOMIDE (5)

Related Pages

PACRITINIB Full Profile All Marrow hyperplasia Drugs PACRITINIB Demographics PACRITINIB Timeline